Chemed (CHE) recently announced a 17% increase to its quarterly cash dividend to US$0.70 per share, which highlights management's confidence in the business and draws fresh attention to the stock's income profile.

Alongside the higher dividend, Chemed's recent share price momentum has been strong, with a 30 day share price return of 9.94% and a 90 day share price return of 26.67%. The 1 year total shareholder return of 21.70% and 5 year total shareholder return of 19.70% suggest that shorter term enthusiasm is building on a longer performance record rather than standing alone.

If this dividend move has you thinking about where else income and growth might come from, it can be useful to scan for other resilient operators. One place to start is our screener of 18 top founder-led companies

Chemed combines growing hospice and plumbing businesses with a long dividend record and a recent 17% raise. After this strong share price run, investors may ask whether the current valuation still leaves enough room for comfort.

Most Popular Narrative: 7.4% Overvalued

Chemed last closed at $537.14, compared with a widely followed narrative fair value of $500. That gap reflects differing views on how durable its hospice and plumbing cash flows could be over time.

An aging US population and management’s intention to pursue additional hospice starts and acquisitions in certificate of need states increase the long term demand pool for VITAS services, which can support sustained growth in average daily census, revenue and earnings.

Want to see what earnings path and margin profile that quote implies for Chemed? The narrative leans on shifting mix, higher profitability and a lower future valuation multiple than many investors might expect.

Result: Fair Value of $500 (OVERVALUED)

However, Chemed’s story also carries some clear watchpoints, including potential Medicare Cap pressures at VITAS and higher digital customer acquisition costs at Roto Rooter that could squeeze margins.

Another View Of Chemed’s Valuation

The narrative fair value for Chemed sits at $500 and points to a 7.4% premium to the recent share price. Our DCF model tells a different story. On that basis, Chemed at $537.14 sits below an estimated future cash flow value of $695.70, which presents the stock as undervalued. Which set of assumptions is closer to your own?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Chemed for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With both risks and rewards in view for Chemed, this is a good moment to move quickly and weigh the trade offs for yourself using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Chemed?

If Chemed has sharpened your focus on quality, do not stop here. Considering a broader range of stock styles can help you build a more resilient portfolio.

• Spot opportunities in smaller companies that still meet strict quality filters by checking the 19 elite penny stocks with strong financials.
• Focus on stocks that combine strong fundamentals with prices below their estimated worth using the 49 high quality undervalued stocks.
• Prioritise resilience by looking at companies that show financial strength and stability through the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.